Navigation Links
Fruitfly Model of a Neuropathic Disease Demonstrates Novel Role for Proteins in the Family of aTyr Pharma's Product Class
Date:7/13/2009

SAN DIEGO, July 13 /PRNewswire/ -- Research published in the June 26, 2009 edition of Proceedings of National Academy of Sciences provides further evidence for novel roles of tRNA synthetases in disease, validating the therapeutic potential for aTyr Pharma's new class of naturally occurring protein agents. The aminoacyl tRNA synthetases are universal and essential components of protein synthesis machinery found in all organisms, but human synthetases have naturally occurring resected variants with potent cell signaling activities that are vital to normal functioning of humans. aTyr Pharma's proprietary product generating engine consists of these resected proteins (resectins) of human aminoacyl tRNA synthetases with cell signaling activities distinct from the protein synthesis activities. In this recently published study, a model of a human neuropathy was created in the fruit fly (Drosophila) by introducing mutations in the tyrosyl-tRNA synthetase which correspond to disease associated mutations in humans. These dominant mutations do not cause a loss in the protein synthesis activity, indicating that the neuropathy arises from distinct activities of this tRNA synthetase. This work provides further proof of noncanonical roles for tRNA synthetases in human disease.

The large team of scientists on the study included Professors Paul Schimmel and Xiang-Lei Yang, scientific co-founders of aTyr Pharma, and Leslie Nangle, Director of Research at aTyr Pharma, and was led by Albena Jordanova of the University of Antwerp. Other scientists contributing to this paper are from the University of Antwerp, Universiteit Leuven, and Florida Atlantic University. Professor Paul Schimmel of The Scripps Research Institute describes the significance of the work. "Charcot-Marie-Tooth (CMT) is one of the most common inherited neurological disorders, with typical symptoms usually emerging in early adulthood, including loss of muscle mass, pain and sensitivity, foot deformations and difficulties in walking. Human genome sequencing revealed that some CMT patients have mutations in a gene encoding tyrosyl-tRNA synthetase. While tRNA synthetases play an essential role in protein synthesis in all forms of life, these dominant mutations in CMT patients did not seem to manifest the disease through disruption of those protein synthesis activities. When the mutations found in humans are introduced into the Drosophila genome, the flies develop neurological defects that correspond to CMT in humans. While we are still trying to understand how mutations in the tRNA synthetase gene disrupt the neurological system of a complex organism, this study showed that there are neurological functions encoded in this gene."

According to Jeff Watkins, CEO of aTyr Pharma, "In the past few years, Professor Schimmel has discovered a whole new area of biology: novel signaling functions for naturally occurring proteins resected from ancient proteins such as tRNA synthetases. This work in Drosophila illustrates a surprising disease-causing role for tRNA synthetases that is not related to the well-studied protein synthesis activities of these enzymes. Instead, in humans and this fruit fly model, the tyrosyl-tRNA synthetase gene encodes a distinct function involved in the complex neurobiology of an organism. These novel activities are seen for other members of the tRNA synthetases family as well, and aTyr Pharma's portfolio capitalizes on this new area of biology by using these naturally occurring resectins with novel signaling activities to treat a wide variety of diseases, such as inflammation, automimmune, hematopoietic and metabolic disorders."

The PNAS publication can be accessed at: http://www.pnas.org/content/early/2009/06/25/0905339106.abstract


'/>"/>
SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
2. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
3. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
6. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
9. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10. Researchers Train the Immune System to Deliver Virus That Destroys Cancer in Lab Models
11. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5 ... , The healthcare industry in the United States has undergone major changes over the ... needing to have a doctor’s order to get a blood test or other lab ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... August 16, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache ...
(Date:8/16/2017)... ... ... Chain”: an inspirational story for those shackled by the chains of a broken life. ... writer and a woman of great faith and wisdom. She is a great motivational ... born and raised in Vero Beach, Florida and has dedicated her life and ministry to ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... of disease. It’s reaching out to a patient who feels isolated. It’s developing ... amid madness. , WesternU President Daniel R. Wilson, MD, PhD, invited three renowned ...
Breaking Medicine News(10 mins):